Understanding how a specific RNA affects liver cancer growth and immune response
Investigating the Immunosuppressive Function of lncRNA CRNDE in Hepatic Tumorigenesis
['FUNDING_R01'] · TULANE UNIVERSITY OF LOUISIANA · NIH-11127286
This study is looking at a specific molecule called CRNDE in liver cancer to see how it affects immune cells that help fight tumors, with the goal of finding new ways to improve treatments for people with liver cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TULANE UNIVERSITY OF LOUISIANA (nih funded) |
| Locations | 1 site (NEW ORLEANS, UNITED STATES) |
| Trial ID | NIH-11127286 on ClinicalTrials.gov |
What this research studies
This research investigates the role of a long non-coding RNA (lncRNA) called CRNDE in liver cancer, specifically hepatocellular carcinoma (HCC). The study aims to understand how CRNDE contributes to the dysfunction of immune cells that typically fight tumors, which may lead to cancer progression. By examining the molecular mechanisms involved, the researchers hope to identify new therapeutic targets that could enhance the effectiveness of immunotherapy for HCC. The research will also test the effects of inhibiting CRNDE in mouse models to evaluate potential treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with hepatocellular carcinoma who may benefit from enhanced immunotherapy treatments.
Not a fit: Patients with liver cancer who do not have a compromised immune response or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy options for patients with liver cancer, potentially enhancing their immune response against tumors.
How similar studies have performed: Previous research has shown promising results in targeting immune checkpoints in cancer, but the specific approach of targeting lncRNA CRNDE in HCC is relatively novel.
Where this research is happening
NEW ORLEANS, UNITED STATES
- TULANE UNIVERSITY OF LOUISIANA — NEW ORLEANS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHANG, JINQIANG — TULANE UNIVERSITY OF LOUISIANA
- Study coordinator: ZHANG, JINQIANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anticancer immunotherapy